OncoMatch/Clinical Trials/NCT07085767
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Is NCT07085767 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Palazestrant and Ribociclib for breast cancer.
Treatment: Palazestrant · Ribociclib · Letrozole — This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
Required: ESR1 positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Cannot have received: endocrine therapy (fulvestrant, elacestrant)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Trial Site · Denver, Colorado
- Clinical Trial Site · Ames, Iowa
- Clinical Trial Site · Scarborough, Maine
- Clinical Trial Site · Kansas City, Missouri
- Clinical Trial Site · Santa Fe, New Mexico
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify